Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment
By Mary de Wet
Relay Therapeutics will collaborate with Pfizer to study atirmociclib in combination with RLY-2608 and fulvestrant in patients with certain types of metastatic breast cancer.
Under the terms of the agreement, Pfizer will provide atirmociclib for the study and Relay will conduct the clinical trial, Relay said Wednesday. The companies plan to begin the study by the end of this year.
Atirmociclib is Pfizer's investigative selective-CDK4 inhibitor, and RLY-2608 is a mutant selective PI3K(alpha) inhibitor. Fulvestrant is already used to treat some types of breast cancer.
The triple combination of drugs will be studied in patients with PI3K(alpha)-mutated, HR+, HER2- metastatic breast cancer. The Centers for Disease Control said almost 240,000 new cases of all types of breast cancer in women were reported in 2020, the latest data available, and 42,273 women died.
Relay has two other drug candidates targeting cancer. The company is collaborating with Genentech to develop GDC-1971 to inhibit the protein tyrosine phosphatase SHP2 that promotes cancer cell survival.
Relay shares were up 5.3% at $7.73 in after-hours trade.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
June 05, 2024 17:53 ET (21:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks